Amgen Inc. (AMGN) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Amgen Inc. (AMGN) trades at a price-to-earnings ratio of 27.3x, with a stock price of $388.16 and trailing twelve-month earnings per share of $14.20.
The current P/E is roughly in line with its 5-year average of 25.7x. Over the past five years, AMGN's P/E has ranged from a low of 15.0x to a high of 53.8x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, AMGN trades at a 15% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 9.27 (P/E divided by 88% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, AMGN trades roughly in line with the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Specialty and biologics-focused pharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ABBVAbbVie Inc. | $410B | 97.1 | - | -12% |
AMGNAmgen Inc. | $209B | 27.3 | 9.27 | +88%Best |
GILDGilead Sciences, Inc. | $186B | 392.0 | - | -92% |
NVONovo Nordisk A/S | $126B | 10.3Lowest | 0.50Best | +2% |
BIIBBiogen Inc. | $28B | 21.7 | - | -21% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $327.31 | $14.23 | 23.0x | -19% |
| FY2025 Q3 | $282.20 | $12.94 | 21.8x | -23% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $279.21 | $12.23 | 22.8x | -20% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $311.55 | $10.96 | 28.4x | +0% |
| FY2024 Q4 | $260.64 | $7.55 | 34.5x | +21% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $322.21 | $7.81 | 41.3x | +45% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $312.45 | $5.81 | 53.8x | +89% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $284.32 | $7.00 | 40.6x | +43% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $288.02 | $12.49 | 23.1x | -19% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $268.76 | $14.07 | 19.1x | -33% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $222.02 | $14.83 | 15.0x | -47% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $241.75 | $14.71 | 16.4x | -42% |
Average P/E for displayed period: 28.4x
See AMGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMGN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AMGN vs AGIO
See how AMGN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AMGN stock overvalued or undervalued?
AMGN trades at 27.3x P/E, near its 5-year average of 25.7x. The 75th percentile ranking places valuation within normal historical bounds.
How does AMGN's valuation compare to peers?
Amgen Inc. P/E of 27.3x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is AMGN's PEG ratio?
AMGN PEG ratio is 9.27. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.